Intra-cellular therapies, inc. to present data on lumateperone and iti 333 at the 58th annual meeting of the american college of neuropsychopharmacology

Intra-cellular therapies, inc. announced that the company will be presenting at the 58th annual meeting of the american college of neuropsychopharmacology (acnp) to be held in hollywood, fl, december 8-11, 2019. intra-cellular therapies will be presenting the following posters and presentations at acnp, which will include results from study 404, a phase 3 clinical trial evaluating lumateperone for the treatment of bipolar depression, as well as new data from the schizophrenia clinical program including the long-term safety study. lumateperone is a novel investigational drug currently under review by the fda as a potential treatment for adults with schizophrenia. preclinical data on iti-333, novel compound with high affinity at serotonin 5-ht2a, dopamine d1 and mu opioid (mop) receptors for the potential treatment of substance use disorders and pain will also be presented.
ITCI Ratings Summary
ITCI Quant Ranking